Skip to Content
 

News: Breast Cancer Research Program

Research team documents potential new treatment path for breast cancer

Friday, January 18th, 2019

Immunotherapies that take off the “brakes” on the adaptive anti-tumor response have worked well in melanoma and lung cancer but less so in breast cancers. That could change.

Breast cancer-killing RIG

Friday, December 14th, 2018

A recent study in the journal Cancer Research demonstrates that a RIG-I agonist has potent immunogenic and therapeutic effects in breast cancer.

Clues to bone metastases

Monday, November 5th, 2018

A recent study by Rachelle Johnson, Ph.D., and colleagues looked at factors influencing the ability of breast cancer cells to colonize bone and enter and exit a dormant state.

Cancer Center investigators awarded Komen grants

Friday, October 12th, 2018

Vanderbilt-Ingram Cancer Center (VICC) investigators have received financial support from Susan G. Komen for breast cancer research.

Team identifies new gene candidates for breast cancer risk

Monday, July 2nd, 2018

A new study has identified 48 candidate susceptibility genes for breast cancer risk, including 14 genes at loci (chromosome regions) not yet reported for breast cancer.

Park named to VICC breast cancer leadership position

Thursday, May 17th, 2018

Ben Ho Park, MD, PhD, has been named co-leader of the Breast Cancer Research Program, director of Precision Oncology and associate director for Translational Research at Vanderbilt-Ingram Cancer Center. He will assume his new post Sept. 1.

VICC breast cancer leaders named Komen Scholars

Friday, April 13th, 2018

Ingrid Mayer, MD, MSCI, Ingram Professor of Cancer Research and leader of the Breast Cancer Research Program, has been named a Komen Scholar for her leadership in breast cancer research. She is joined by Wayne Dornan, PhD, a patient research advocate at VICC, who will serve on the Advocates in Science Steering Committee for Susan G. Komen.

Study seeks to boost breast tumor immune response

Thursday, February 8th, 2018

Targeting specific molecules in breast tumors, called methylating agents, can turn up the immune response, potentially making tumors responsive to immunotherapy, suggests a new study published in Nature Communications.

Macara named ‘Pink Tie Guy’ for Komen breast cancer research

Thursday, January 11th, 2018

Ian Macara, PhD, Louise B. McGavock Professor and Chair of Cell and Developmental Biology and co-leader of the Signal Transduction and Chemical Biology Research Program at Vanderbilt-Ingram Cancer Center (VICC), has been named one of the Pink Tie Guys for the Susan G. Komen Central Tennessee organization.

Study to test combination therapy for breast cancer

Friday, October 27th, 2017

Vanderbilt-Ingram Cancer Center has received $2.3 million to fund a clinical research trial testing a combination of three immunotherapy compounds for patients with a specific type of advanced breast cancer.

Next Page »